Healthdirect Free Australian health advice you can count on.
Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately
healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.
Emergency for Queensland, Cyclone Alfred
Health services may not be operating as usual in parts of Queensland and NSW. Check the healthdirect Service Finder for the latest information on health services in your area.
To seek advice or assistance in Queensland, call 13 Health (13 43 25 84), otherwise call healthdirect on 1800 022 222. For urgent help from police, fire or ambulance services, call triple zero (000).
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
RIVOXA, in combination with aspirin, is indicated for:
The prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
RIVOXA is indicated for:
Prevention of venous thromboembolism (VTE) in adult patients who have undergone major orthopaedic surgery of thelower limbs (elective total hip replacement, treatment for up to 5weeks; elective total knee replacement, treatment for up to 2 weeks).
Prevention of stroke and systemic embolism in patients withnon-valvular atrial fibrillation and at least one additional risk factor for stroke.
Treatment of deep vein thrombosis (DVT) and pulmonaryembolism (PE) and for the prevention of recurrent DVT and PE.
RIVOXA in combination with aspirin, is indicated for:
The prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
RIVOXA is indicated for:
Prevention of venous thromboembolism (VTE) in adult patients who have undergone major orthopaedic surgery of thelower limbs (elective total hip replacement, treatment for up to 5weeks; elective total knee replacement, treatment for up to 2 weeks).
Prevention of stroke and systemic embolism in patients withnon-valvular atrial fibrillation and at least one additional risk factor for stroke.
Treatment of deep vein thrombosis (DVT) and pulmonaryembolism (PE) and for the prevention of recurrent DVT and PE.
RIVOXA in combination with aspirin, is indicated for:
The prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
RIVOXA is indicated for:
Prevention of venous thromboembolism (VTE) in adult patients who have undergone major orthopaedic surgery of thelower limbs (elective total hip replacement, treatment for up to 5weeks; elective total knee replacement, treatment for up to 2 weeks).
Prevention of stroke and systemic embolism in patients withnon-valvular atrial fibrillation and at least one additional risk factor for stroke.
Treatment of deep vein thrombosis (DVT) and pulmonaryembolism (PE) and for the prevention of recurrent DVT and PE.
RIVOXA in combination with aspirin, is indicated for:
The prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
RIVOXA is indicated for:
Prevention of venous thromboembolism (VTE) in adult patients who have undergone major orthopaedic surgery of thelower limbs (elective total hip replacement, treatment for up to 5weeks; elective total knee replacement, treatment for up to 2 weeks).
Prevention of stroke and systemic embolism in patients withnon-valvular atrial fibrillation and at least one additional risk factor for stroke.
Treatment of deep vein thrombosis (DVT) and pulmonaryembolism (PE) and for the prevention of recurrent DVT and PE.
RIVOXA in combination with aspirin, is indicated for:
The prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
RIVOXA is indicated for:
Prevention of venous thromboembolism (VTE) in adult patients who have undergone major orthopaedic surgery of thelower limbs (elective total hip replacement, treatment for up to 5weeks; elective total knee replacement, treatment for up to 2 weeks).
Prevention of stroke and systemic embolism in patients withnon-valvular atrial fibrillation and at least one additional risk factor for stroke.
Treatment of deep vein thrombosis (DVT) and pulmonaryembolism (PE) and for the prevention of recurrent DVT and PE.
RIVOXA in combination with aspirin, is indicated for:
The prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD)
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
